Alexander M.M. Eggermont

59.8k total citations · 8 hit papers
389 papers, 25.8k citations indexed

About

Alexander M.M. Eggermont is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Alexander M.M. Eggermont has authored 389 papers receiving a total of 25.8k indexed citations (citations by other indexed papers that have themselves been cited), including 298 papers in Oncology, 121 papers in Molecular Biology and 97 papers in Immunology. Recurrent topics in Alexander M.M. Eggermont's work include Cutaneous Melanoma Detection and Management (196 papers), CAR-T cell therapy research (103 papers) and Immunotherapy and Immune Responses (83 papers). Alexander M.M. Eggermont is often cited by papers focused on Cutaneous Melanoma Detection and Management (196 papers), CAR-T cell therapy research (103 papers) and Immunotherapy and Immune Responses (83 papers). Alexander M.M. Eggermont collaborates with scholars based in Netherlands, France and Germany. Alexander M.M. Eggermont's co-authors include Caroline Robert, Timo L.M. ten Hagen, John F. Thompson, Alan Spatz, Cornelis Verhoef, Jeffrey E. Gershenwald, John M. Kirkwood, Merrick I. Ross, Vernon K. Sondak and Charles M. Balch and has published in prestigious journals such as Nature, The Lancet and Nature Communications.

In The Last Decade

Alexander M.M. Eggermont

381 papers receiving 25.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final Version of 2009 AJCC Melanoma Staging and Classification

2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

2017 1.4k citations Jeffrey E. Gershenwald, Vernon K. Sondak et al. profile →
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

2017 972 citations Nathalie Chaput, Émilie Routier et al. profile →
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

2016 867 citations Stéphane Champiat, Laurent Dercle et al. Clinical Cancer Research profile →
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

2016 813 citations Émilie Routier, Aurélien Marabelle et al. Nature Reviews Clinical Oncology profile →
TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical Utility

2006 578 citations Alexander M.M. Eggermont et al. profile →
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

2017 434 citations Paolo A. Ascierto, Alexander M.M. Eggermont et al. European Journal of Cancer profile →
Clinical and translational attributes of immune-related adverse events

2024 50 citations Alexander M.M. Eggermont et al. profile →

Peers

Countries citing papers authored by Alexander M.M. Eggermont

Since Specialization

Citations

This map shows the geographic impact of Alexander M.M. Eggermont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander M.M. Eggermont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander M.M. Eggermont more than expected).

Fields of papers citing papers by Alexander M.M. Eggermont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander M.M. Eggermont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander M.M. Eggermont. The network helps show where Alexander M.M. Eggermont may publish in the future.

Co-authorship network of co-authors of Alexander M.M. Eggermont

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander M.M. Eggermont. A scholar is included among the top collaborators of Alexander M.M. Eggermont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander M.M. Eggermont. Alexander M.M. Eggermont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Perspectives on the role of “-Omics” in predicting response to immunotherapy 2025 ·European Journal of Cancer ·(unknown), Sumit K. Subudhi, Wim Vos, Massimo Andreatta, Santiago J. Carmona, (unknown), Barbara Seliger, Ramy Ibrahim, (unknown), Michael A. Smith, Alexander M.M. Eggermont, Bernard A. Fox, Michele Maio	2
2	Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study 2024 ·Journal of Clinical Oncology ·Jason J. Luke, Paolo A. Ascierto, Muhammad A. Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, Xi Wu, Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Georgina V. Long	43
3	Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. 2023 ·Journal of Clinical Oncology ·Jason J. Luke, Paolo A. Ascierto, Muhammad Adnan Khattak, Luis de la Cruz‐Merino, Michele Del Vecchio, Piotr Rutkowski, Francesco Spagnolo, Jacek Mackiewicz, Vanna Chiarion‐Sileni, John M. Kirkwood, Caroline Robert, Jean‐Jacques Grob, Federica De Galitiis, Dirk Schadendorf, Matteo S. Carlino, (unknown), Mizuho Fukunaga‐Kalabis, Clemens Krepler, Alexander M.M. Eggermont, Georgina V. Long	7
4	The “Great Debate” at Melanoma Bridge 2022, Naples, December 1st–3rd, 2022 2023 ·Journal of Translational Medicine ·Paolo A. Ascierto, Christian U. Blank, Alexander M.M. Eggermont, Claus Garbe, Jeffrey E. Gershenwald, Omid Hamid, Axel Hauschild, Jason J. Luke, Janice M. Mehnert, Jeffrey A. Sosman, Hussein A. Tawbi, Mario Mandalà, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov	2
5	Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types 2023 ·European Journal of Cancer ·Jammbe Musoro, Corneel Coens, Mirjam A. G. Sprangers, Yvonne Brandberg, Mogens Grøenvold, Hans‐Henning Flechtner, Kim Cocks, Galina Velikova, Linda Dirven, Elfriede Greimel, Susanne Singer, Katarzyna Pogoda, Eva‐Maria Gamper, Samantha C. Sodergren, Alexander M.M. Eggermont, Michael Koller, Jaap C. Reijneveld, Martin Taphoorn, Madeleine King, Andrew Bottomley	64
6	COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma 2023 ·Future Oncology ·Alexander C. J. van Akkooi, Axel Hauschild, Georgina V. Long, Mario Mandalà, Michal Kiciński, Anne-Sophie Govaerts, (unknown), M. Ouali, Paul Lorigan, Alexander M.M. Eggermont	11
7	Optimal systemic therapy for high-risk resectable melanoma 2022 ·Nature Reviews Clinical Oncology ·Alexander M.M. Eggermont, Omid Hamid, Georgina V. Long, Jason J. Luke	11
8	The “Great Debate” at Melanoma Bridge 2020: December, 5th, 2020 2021 ·Journal of Translational Medicine ·Paolo A. Ascierto, Michael B. Atkins, Alexander M.M. Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman, Igor Puzanov	1
9	Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas 2021 ·European Journal of Cancer ·Lars H. Lindner, Jean‐Yves Blay, Alexander M.M. Eggermont, Rolf D. Issels	9
10	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial 2019 ·European Journal of Cancer ·Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto, Jon Richards, Célèste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S. Weber, Michele Maio, Fareeda Hosein, Veerle de Pril, Michal Kiciński, Stefan Suciu, Alessandro Testori	123
11	The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018 2019 ·Journal of Translational Medicine ·Paolo A. Ascierto, Paolo Bruzzi, Alexander M.M. Eggermont, Omid Hamid, Hussein A. Tawbi, Alexander C. J. van Akkooi, Alessandro Testori, Corrado Caracò, Igor Puzanov, Francesco Perrone	1
12	Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 breakdown → 2016 ·Clinical Cancer Research ·Stéphane Champiat, Laurent Dercle, Samy Ammari, Christophe Massard, Antoine Hollebecque, Sophie Postel‐Vinay, Nathalie Chaput, Alexander M.M. Eggermont, Aurélien Marabelle, Jean‐Charles Soria, Charles Ferté	867
13	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF–CRAF Heterodimerization 2016 ·Cancer Research ·Lise Boussemart, Isabelle Girault, Hélène Malka-Mahieu, Christine Mateus, Émilie Routier, (unknown), Nyam Kamsu-Kom, M. Thomas, Gorana Tomasic, Sandrine Agoussi, (unknown), Mélanie Laporte, Ludovic Lacroix, Alexander M.M. Eggermont, Andréa Cavalcanti, Florent Grange, Julien Adam, Stéphan Vagner, Caroline Robert	33
14	ecancermedicalscience 2016 ·ecancermedicalscience ·Alessandro Testori, Javier Soteldo, B. Powell, François Salès, Lorenzo Borgognoni, Piotr Rutkowski, F. Lejeune, (unknown), Alexander M.M. Eggermont	6
15	Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma 2012 ·Journal of Clinical Oncology ·Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Mario Santinami, Wim H.J. Kruit, Jeremy Marsden, Cornelis J.A. Punt, François Salès, Reinhard Dummer, Caroline Robert, Dirk Schadendorf, (unknown), Gaetan de Schaetzen, Alan Spatz, Ulrich Keilholz	190
16	Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database 2011 ·Journal of Clinical Oncology ·John F. Thompson, Seng-Jaw Soong, Charles M. Balch, Jeffrey E. Gershenwald, Shouluan Ding, Daniel G. Coit, Keith T. Flaherty, Phyllis A. Gimotty, T. M. Johnson, Marcella M. Johnson, Stanley P. L. Leong, Merrick I. Ross, David R. Byrd, Natale Cascinelli, Alistair J. Cochran, Alexander M.M. Eggermont, Kelly M. McMasters, Martín C. Mihm, Donald L. Morton, Vernon K. Sondak	250
17	Multivariate Analysis of Prognostic Factors Among 2,313 Patients With Stage III Melanoma: Comparison of Nodal Micrometastases Versus Macrometastases 2010 ·Journal of Clinical Oncology ·Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong, John F. Thompson, Shouluan Ding, David R. Byrd, Natale Cascinelli, Alistair J. Cochran, Daniel G. Coit, Alexander M.M. Eggermont, Timothy M. Johnson, John M. Kirkwood, Stanley P. L. Leong, Kelly M. McMasters, Martín C. Mihm, Donald L. Morton, Merrick I. Ross, Vernon K. Sondak	287
18	Final Version of 2009 AJCC Melanoma Staging and Classification breakdown → 2009 ·Journal of Clinical Oncology ·Charles M. Balch, Jeffrey E. Gershenwald, Seng-Jaw Soong, John F. Thompson, Michael B. Atkins, David R. Byrd, Antônio C. Buzaid, Alistair J. Cochran, Daniel G. Coit, Shouluan Ding, Alexander M.M. Eggermont, Keith T. Flaherty, Phyllis A. Gimotty, John M. Kirkwood, Kelly M. McMasters, Martín C. Mihm, Donald L. Morton, Merrick I. Ross, Arthur J. Sober, Vernon K. Sondak	3342
19	Regional Cancer Therapy 2007 ·Humana Press eBooks ·Peter M. Schlag, Ulrike Stein, Alexander M.M. Eggermont	11
20	Characteristics of recovery from the euthyroid sick syndrome induced by tumor necrosis factor alpha in cancer patients 1999 ·Metabolism ·Richard A. Feelders, A. J. G. Swaak, Johannes A. Romijn, Alexander M.M. Eggermont, Emile T. Tielens, (unknown), Erik Endert, H.G. van Eijk, Arie Berghout	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact